Natera Shares Surge on Stellar Quarterly Performance
Published on 11/12/2025 at 12:02 | Redaktion boerse-global.de
Genetic testing specialist Natera has delivered a quarterly report that significantly surpassed market forecasts, propelling its stock upward. The company reported substantial revenue growth and margin expansion, concurrently raising its full-year guidance. However, this impressive performance is tempered by persistent financial losses, presenting a critical challenge for the high-flying equity.
Natera’s third quarter for fiscal year 2025 proved exceptionally strong. Company revenue surged 34.7% to reach $592.2 million, a jump primarily fueled by escalating demand for its diagnostic tests. The oncology segment demonstrated particularly vigorous expansion, with testing volumes climbing 53.9%.
The company’s profitability metrics also showed marked improvement. The gross margin advanced to 64.9%, indicating that Natera’s growth is becoming Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
